Methods of treating melanoma
Provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein.
1. A method of treating melanoma in a human individual comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising paclitaxel and an albumin, wherein the individual is selected for treatment based on the individual having a melanoma comprising a V600E mutation in BRAF and wherein the composition is administered intravenously and the dose of paclitaxel in the composition is about 80 mg/m 2 to about 200 mg/m 2 .
2. The method of claim 1 , wherein the individual is selected for treatment based on the individual having metastatic melanoma at stage M1c.
3. The method of claim 1 , wherein the individual is selected for treatment based on the individual having a serum LDH level of between about 1.1× to about 2.0×ULN.
4. The method of claim 1 , wherein the method further comprises a second therapy.
5. The method of claim 4 , wherein the method comprises administration of at least one other therapeutic agent.
6. The method of claim 5 , wherein the other therapeutic agent is a BRAF inhibitor.
7. The method of claim 5 , wherein the other therapeutic agent is Ipilimumab.
8. The method of claim 1 , wherein the method is used as a first line therapy.
9. The method of claim 1 , wherein the method is used as a second line therapy.
10. The method of claim 1 , wherein the dose of paclitaxel in the nanoparticle composition is about 150 mg/m 2 .
11. The method of claim 1 , wherein the composition comprising nanoparticles comprising paclitaxel and an albumin is administered weekly.
12. The method of claim 11 , wherein the composition comprising nanoparticles comprising paclitaxel and an albumin is administered on days 1, 8, and 15 of a 28-day treatment cycle.
13. The method of claim 1 , wherein the albumin is human serum albumin.
14. The method of claim 1 , wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm.
15. The method of claim 1 , wherein the weight ratio of albumin and paclitaxel in the nanoparticle composition is about 9:1 or less.
16. The method of claim 1 , wherein the paclitaxel in the nanoparticles are coated with the albumin.